论文部分内容阅读
目的探讨胺碘酮联合厄贝沙坦治疗心力衰竭合并心律失常的临床效果,分析研究其作用机制。方法 160例心力衰竭合并心律失常患者,按照入院顺序编号分为对照组及观察组,各80例。对照组给予胺碘酮治疗,观察组在对照组基础上加用厄贝沙坦治疗。比较两组治疗效果及不良反应。结果观察组总有效率为92.5%,高于对照组的72.5%,差异具有统计学意义(P<0.05)。观察组不良反应发生率为3.8%,对照组为5.0%,比较差异无统计学意义(P>0.05)。结论胺碘酮联合厄贝沙坦治疗心力衰竭合并心律失常疗效确切,安全性高,值得临床推广。
Objective To investigate the clinical effect of amiodarone combined with irbesartan in the treatment of heart failure with arrhythmia, and analyze the mechanism of action. Methods A total of 160 patients with heart failure and arrhythmia were divided into control group and observation group according to the order of hospitalization, 80 cases each. The control group was treated with amiodarone. The observation group was treated with irbesartan on the basis of the control group. The therapeutic effects and adverse reactions of the two groups were compared. Results The total effective rate in observation group was 92.5%, which was higher than that in control group (72.5%), the difference was statistically significant (P <0.05). The incidence of adverse reactions in the observation group was 3.8% and in the control group was 5.0%, the difference was not statistically significant (P> 0.05). Conclusion Amiodarone combined with irbesartan in the treatment of heart failure with arrhythmia is effective, safe and worthy of clinical promotion.